Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis

Vaccine

Volumn 28, Issue 48, 2010, Pages 7683-7689

  Bhattacharya, Debaditya ^a   Mecsas, Joan ^b   Hu, Linden T ^c  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

F1; LcrV; Plague; Vaccinia virus

Indexed keywords

BACTERIAL PROTEIN; PROTEIN F1; PROTEIN VP37; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DISEASE TRANSMISSION; DRUG EFFICACY; LETHAL DOSE; MALE; NONHUMAN; PLAGUE; PRIORITY JOURNAL; VACCINATION; VACCINIA VIRUS; WILD ANIMAL; YERSINIA PESTIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; DISEASE RESERVOIRS; MALE; MICE; MICE, INBRED C57BL; PLAGUE; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEINS; RECOMBINANT FUSION PROTEINS; VACCINES, DNA; VACCINIA VIRUS; YERSINIA PESTIS;

EID: 78249243856     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.039     Document Type: Article

References (67)

1. Plague 1998, Arnold, London. 9th ed. K.L. Gage (Ed.).
2. Gage K.L., Kosoy M.Y. Natural history of plague: perspectives from more than a century of research. Annu Rev Entomol 2005, 50:505-528.
3. Stenseth N.C., Atshabar B.B., Begon M., Belmain S.R., Bertherat E., Carniel E., et al. Plague: past, present, and future. PLoS Med 2008, 5(1):e3.
4. Christie A.B. Plague: review of ecology. Ecol Dis 1982, 1(2-3):111-115.
5. Craven R.B., Maupin G.O., Beard M.L., Quan T.J., Barnes A.M. Reported cases of human plague infections in the United States, 1970-1991. J Med Entomol 1993, 30(4):758-761.
6. Gage K.L., Lance S.E., Dennis D.T., Montenieri J.A. Human plague in the United States: a review of cases from 1988-1992 with comments on the likelihood of increased plague activity. Border Epidemiol Bull 1992, 19:1-10.
7. Perry R.D., Fetherston J.D. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 1997, 10(1):35-66.
8. Velimirovic B. Plague and glasnost. First information about human cases in the USSR in 1989 and 1990. Infection 1990, 18(6):388-393.
9. Cavanaugh D.C., Elisberg B.L., Llewellyn C.H., Marshall J.D., Rust J.H., Williams J.E., et al. Plague immunization. V. Indirect evidence for the efficacy of plague vaccine. J Infect Dis 1974, 129(Suppl):S37-40.
10. Titball R.W., Williamson E.D. Vaccination against bubonic and pneumonic plague. Vaccine 2001, 19(30):4175-4184.
11. Oyston P.C., Russell P., Williamson E.D., Titball R.W. An aroA mutant of Yersinia pestis is attenuated in guinea-pigs, but virulent in mice. Microbiology 1996, 142(Pt 7):1847-1853.
12. Robinson V.L., Oyston P.C., Titball R.W. A dam mutant of Yersinia pestis is attenuated and induces protection against plague. FEMS Microbiol Lett 2005, 252(2):251-256.
13. Russell P., Eley S.M., Hibbs S.E., Manchee R.J., Stagg A.J., Titball R.W. A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 1995, 13(16):1551-1556.
14. Taylor V.L., Titball R.W., Oyston P.C. Oral immunization with a dam mutant of Yersinia pseudotuberculosis protects against plague. Microbiology 2005, 151(Pt 6):1919-1926.
15. Andrews G.P., Heath D.G., Anderson G.W., Welkos S.L., Friedlander A.M. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 1996, 64(6):2180-2187.
16. Andrews G.P., Strachan S.T., Benner G.E., Sample A.K., Anderson G.W., Adamovicz J.J., et al. Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis. Infect Immun 1999, 67(3):1533-1537.
17. Matson J.S., Durick K.A., Bradley D.S., Nilles M.L. Immunization of mice with YscF provides protection from Yersinia pestis infections. BMC Microbiol 2005, 5:38.
18. Williamson E.D., Eley S.M., Griffin K.F., Green M., Russell P., Leary S.E., et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 1995, 12(3-4):223-230.
19. Anderson G.W., Leary S.E., Williamson E.D., Titball R.W., Welkos S.L., Worsham P.L., et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun 1996, 64(11):4580-4585.
20. Liu W.T., Hsu H.L., Liang C.C., Chuang C.C., Lin H.C., Liu Y.T. A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen. FEMS Immunol Med Microbiol 2007, 51(1):58-69.
21. Miller J., Williamson E.D., Lakey J.H., Pearce M.J., Jones S.M., Titball R.W. Macromolecular organisation of recombinant Yersinia pestis F1 antigen and the effect of structure on immunogenicity. FEMS Immunol Med Microbiol 1998, 21(3):213-221.
22. Titball R.W., Howells A.M., Oyston P.C., Williamson E.D. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect Immun 1997, 65(5):1926-1930.
23. Williamson E.D. Plague vaccine research and development. J Appl Microbiol 2001, 91(4):606-608.
24. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., Titball R.W. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 2000, 19(4-5):566-571.
25. Williamson E.D., Flick-Smith H.C., Lebutt C., Rowland C.A., Jones S.M., Waters E.L., et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 2005, 73(6):3598-3608.
26. Williamson E.D., Vesey P.M., Gillhespy K.J., Eley S.M., Green M., Titball R.W. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol 1999, 116(1):107-114.
27. Du Y., Rosqvist R., Forsberg A. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect Immun 2002, 70(3):1453-1460.
28. Mueller C.A., Broz P., Cornelis G.R. The type III secretion system tip complex and translocon. Mol Microbiol 2008, 68(5):1085-1095.
29. Anderson G.W., Worsham P.L., Bolt C.R., Andrews G.P., Welkos S.L., Friedlander A.M., et al. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am J Trop Med Hyg 1997, 56(4):471-473.
30. Motin V.L., Nakajima R., Smirnov G.B., Brubaker R.R. Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun 1994, 62(10):4192-4201.
31. Sato K., Nakajima R., Hara F., Une T., Osada Y. Preparation of monoclonal antibody to V antigen from Yersinia pestis. Contrib Microbiol Immunol 1991, 12:225-229.
32. Klempner M.S., Unnasch T.R., Hu L.T. Taking a bite out of vector-transmitted infectious diseases. N Engl J Med 2007, 356(25):2567-2569.
33. Brochier B., Blancou J., Thomas I., Languet B., Artois M., Kieny M.P., et al. Use of recombinant vaccinia-rabies glycoprotein virus for oral vaccination of wildlife against rabies: innocuity to several non-target bait consuming species. J Wildl Dis 1989, 25(4):540-547.
34. Brochier B., Kieny M.P., Costy F., Coppens P., Bauduin B., Lecocq J.P., et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 1991, 354(6354):520-522.
35. Laine M., Niin E., Partel A. The rabies elimination programme in Estonia using oral rabies vaccination of wildlife: preliminary results. Dev Biol (Basel) 2008, 131:239-247.
36. Matouch O., Vitasek J., Semerad Z., Malena M. Rabies-free status of the Czech Republic after 15 years of oral vaccination. Rev Sci Tech 2007, 26(3):577-584.
37. Rosatte R.C., Donovan D., Davies J.C., Allan M., Bachmann P., Stevenson B., et al. Aerial distribution of ONRAB baits as a tactic to control rabies in raccoons and striped skunks in Ontario, Canada. J Wildl Dis 2009, 45(2):363-374.
38. Rosatte R., Allan M., Bachmann P., Sobey K., Donovan D., Davies J.C., et al. Prevalence of tetracycline and rabies virus antibody in raccoons, skunks, and foxes following aerial distribution of V-RG baits to control raccoon rabies in Ontario, Canada. J Wildl Dis 2008, 44(4):946-964.
39. Hostnik P., Toplak I., Barlic-Maganja D., Grom J., Bidovec A. Control of rabies in Slovenia. J Wildl Dis 2006, 42(2):459-465.
40. Sidwa T.J., Wilson P.J., Moore G.M., Oertli E.H., Hicks B.N., Rohde R.E., et al. Evaluation of oral rabies vaccination programs for control of rabies epizootics in coyotes and gray foxes: 1995-2003. J Am Vet Med Assoc 2005, 227(5):785-792.
41. Expression of proteins in mammalian cells using vaccinia viral vectors 1991, John Wiley & Sons Inc., New York. B. Moss (Ed.).
42. Lahteenmaki K., Virkola R., Saren A., Emody L., Korhonen T.K. Expression of plasminogen activator pla of Yersinia pestis enhances bacterial attachment to the mammalian extracellular matrix. Infect Immun 1998, 66(12):5755-5762.
43. Perry R.D., Straley S.C., Fetherston J.D., Rose D.J., Gregor J., Blattner F.R. DNA sequencing and analysis of the low-Ca2+-response plasmid pCD1 of Yersinia pestis KIM5. Infect Immun 1998, 66(10):4611-4623.
44. Blasco R., Moss B. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 1995, 158(2):157-162.
45. Scheckelhoff M.R., Telford S.R., Hu L.T. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Vaccine 2006, 24(11):1949-1957.
46. Welkos S., O'Brien A. Determination of median lethal and infectious doses in animal model systems. Methods Enzymol 1994, 235:29-39.
47. Reed L.J., Münch H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27(3):5.
48. Gipson C.L., Davis N.L., Johnston R.E., de Silva A.M. Evaluation of Venezuelan Equine Encephalitis (VEE) replicon-based Outer surface protein A (OspA) vaccines in a tick challenge mouse model of Lyme disease. Vaccine 2003, 21(25-26):3875-3884.
49. Heath D.G., Anderson G.W., Mauro J.M., Welkos S.L., Andrews G.P., Adamovicz J., et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998, 16(11-12):1131-1137.
50. Rocke T.E., Smith S., Marinari P., Kreeger J., Enama J.T., Powell B.S. Vaccination with F1-V fusion protein protects black-footed ferrets (Mustela nigripes) against plague upon oral challenge with Yersinia pestis. J Wildl Dis 2008, 44(1):1-7.
51. Jarrett C.O., Sebbane F., Adamovicz J.J., Andrews G.P., Hinnebusch B.J. Flea-borne transmission model to evaluate vaccine efficacy against naturally acquired bubonic plague. Infect Immun 2004, 72(4):2052-2056.
52. Friedlander A.M., Welkos S.L., Worsham P.L., Andrews G.P., Heath D.G., Anderson G.W., et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin Infect Dis 1995, 21(Suppl. 2):S178-S181.
53. Roggenkamp A., Geiger A.M., Leitritz L., Kessler A., Heesemann J. Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect Immun 1997, 65(2):446-451.
54. Anisimov A.P., Lindler L.E., Pier G.B. Intraspecific diversity of Yersinia pestis. Clin Microbiol Rev 2004, 17(2):434-464.
55. Matouch O., Vitasek J., Semerad Z., Malena M. Elimination of rabies in the Czech Republic. Dev Biol (Basel) 2006, 125:141-143.
56. Rupprecht C.E., Hanlon C.A., Slate D. Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control. Dev Biol (Basel) 2004, 119:173-184.
57. Human vaccinia infection after contact with a raccoon rabies vaccine bait-Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 2009;58(43):1204-7.
58. Rupprecht C.E., Blass L., Smith K., Orciari L.A., Niezgoda M., Whitfield S.G., et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med 2001, 345(8):582-586.
59. Moss B. Molecular biology of poxviruses. Recombinant poxviruses 1992, CRC Press, Boca Raton, p. 45-80.
60. Emerson G.L., Li Y., Frace M.A., Olsen-Rasmussen M.A., Khristova M.L., Govil D., et al. The phylogenetics and ecology of the orthopoxviruses endemic to North America. PLoS One 2009, 4(10):e7666.
61. Begon M., Hazel S.M., Baxby D., Bown K., Cavanagh R., Chantrey J., et al. Transmission dynamics of a zoonotic pathogen within and between wildlife host species. Proc Biol Sci 1999, 266(1432):1939-1945.
62. Chantrey J., Meyer H., Baxby D., Begon M., Bown K.J., Hazel S.M., et al. Cowpox: reservoir hosts and geographic range. Epidemiol Infect 1999, 122(3):455-460.
63. Hazel S.M., Bennett M., Chantrey J., Bown K., Cavanagh R., Jones T.R., et al. A longitudinal study of an endemic disease in its wildlife reservoir: cowpox and wild rodents. Epidemiol Infect 2000, 124(3):551-562.
64. Rocke T.E., Iams K.P., Dawe S., Smith S.R., Williamson J.L., Heisey D.M., et al. Further development of raccoon poxvirus-vectored vaccines against plague (Yersinia pestis). Vaccine 2009, 28(2):338-344.
65. Rocke T.E., Dein F.J., Fuchsberger M., Fox B.C., Stinchcomb D.T., Osorio J.E. Limited infection upon human exposure to a recombinant raccoon pox vaccine vector. Vaccine 2004, 22(21-22):2757-2760.
66. Omlin D. Tools for safety assessment-vaccinia-derived recombinant rabies vaccine 1997, Swiss National Science Foundation.
67. Root J.J., McLean R.G., Slate D., MacCarthy K.A., Osorio J.E. Potential effect of prior raccoonpox virus infection in raccoons on vaccinia-based rabies immunization. BMC Immunol 2008, 9:57.